3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
251
Neoplasms, Plasma Cell
91
Lymphoma, Non-Hodgkin
33
Hodgkin Disease
33
Leukemia, Lymphocytic, Chronic, B-Cell
30
Lymphoma
29
Leukemia
29
Immunoglobulin Light-chain Amyloidosis
29
Myelodysplastic Syndromes
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Leukemia, Myeloid, Acute
25
Lymphoma, Mantle-Cell
20
Lymphoma, Follicular
20
Myeloproliferative Disorders
19
Lymphoma, Large B-Cell, Diffuse
19
Lymphoma, B-Cell, Marginal Zone
19
Recurrence
17
Lymphoma, Large-Cell, Immunoblastic
17
Burkitt Lymphoma
17
Primary Myelofibrosis
14
Congenital Abnormalities
14
Anemia, Aplastic
13
Waldenstrom Macroglobulinemia
12
Leukemia, Myeloid, Chronic-Phase
12
Leukemia, Myeloid, Accelerated Phase
12
Leukemia, Myelomonocytic, Chronic
11
Hematologic Neoplasms
11
Graft vs Host Disease
11
Dendritic Cell Sarcoma, Interdigitating
10
Lymphoma, T-Cell, Cutaneous
9
Interventions
Lenalidomide
4
Dexamethasone
4
Bortezomib
3
pomalidomide
2
Cyclophosphamide
2
ricolinostat
1
Zoledronic Acid
1
Vitamin D
1
Transplantation, Autologous
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Calcium Dobesilate
1
Calcium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Melphalan
×
Plasma cell
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts